A Phase II Clinical Trial of Efficacy and Safety of SAL0140 at Different Doses in Patients With Chronic Kidney Disease

Sponsor
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Study ID
NCT07647133
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • SAL0140 Tablets — DRUG
    SAL0140 Tablets
  • SAL0140 Tablets — DRUG
    SAL0140 Tablets
  • SAL0140 placebo — DRUG
    placebo

Study Details

This study will evaluate the efficacy and safety of SAL0140 in patients with chronic kidney disease (CKD).

Key Dates

First listed
Jun 15, 2026
Start date
Jun 15, 2026
Status verified
Jun 2026
Primary completion
Oct 8, 2027
Completion
Dec 31, 2027

Study Design

Enrollment
249 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Low-dose group
  • Experimental: High-dose group
  • Placebo Comparator: Placebo group

Primary Outcome Measure

The baseline change of UACR [ Time Frame: at week 16 ]

Central Contacts

Find similar trials

Nationwide
Chronic kidney disease trialsNephrology trialsKidney disease trials

Related Studies